Nicotine replacement doesn't increase cardio risk after ACS

September 17, 2012
Nicotine replacement doesn't increase cardio risk after ACS
Use of nicotine replacement therapy does not increase the risk of adverse cardiovascular events in the first year following acute coronary syndromes, according to research published in the Oct. 1 issue of The American Journal of Cardiology.

(HealthDay)—Use of nicotine replacement therapy (NRT) does not increase the risk of adverse cardiovascular events in the first year following acute coronary syndromes (ACS), according to research published in the Oct. 1 issue of The American Journal of Cardiology.

Kevin J. Woolf, M.D., of the University of Rochester Medical Center in New York, and colleagues conducted a study involving 663 smokers with ACS, identified from a pre-existing database, who were separated into NRT (184 participants) or control (479 participants) groups based on whether they had been prescribed NRT on hospital discharge.

Of the cohort, 202 had adverse events into the first year following ACS. The researchers observed no significant difference between the groups for the one-year combined end point of death; myocardial infarction; repeat revascularization; or rehospitalization for angina, , or arrhythmia. In addition, no significant difference was found between the groups at one-year for each individual end point.

"The results of the present study suggest that NRT use after ACS was not associated with an increased risk of adverse cardiovascular events," the authors write. "These results might be particularly important in the treatment of smokers with , because the use of medication to stop smoking roughly doubles the success rates in long-term abstinence by reducing withdrawal symptoms."

Explore further: Nicotine replacement therapies may not be effective in helping people quit smoking, study says

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Global platelet reactivity and high risk ACS patients

August 28, 2012

Global platelet reactivity is more effective than responsiveness to clopidogrel in identifying acute coronary syndrome (ACS) patients at high risk of ischemic events, according to research presented at ESC Congress 2012.

Recommended for you

Regular exercise critical for heart health, longevity

January 18, 2016

The majority of citizens in developed countries should not be concerned by potential harm from exercise but rather by the lack of exercise in their lives, according to a clinical perspective published today in the Journal ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.